Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Gut. 2017 Oct 5;67(11):1995–2005. doi: 10.1136/gutjnl-2016-313372

Figure 5. Average of selected markers (ASM) incfDNA dynamics assessment in mCRC patients treated with temozolomide within a clinical trial.

Figure 5

A: Comparison of ASM changes to response status and RECIST. The best ASM changes were plotted as a waterfall plot. Response status of patients evaluated by RECIST is plotted as a heatmap. B: Progression free survival according to best ASM change. Negative ASM change shows a trend for improved PFS.